REG - IXICO plc - PDMR Dealing
RNS Number : 3669NIXICO plc29 January 2021
IXICO plc
("IXICO" or the "Company")
PDMR Dealing
Issue of Equity on exercise of options
IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that it has made an application to the London Stock Exchange for the admission to trading on AIM of 156,471 new ordinary shares of 1p each ("New Shares") to satisfy the exercise of options by the VP Alliance Management (PDMR).
The New Shares are expected to be admitted to trading on AIM on 5 February 2021.
Total voting rights
Application has been made for admission to trading on AIM of 156,471 New Shares. Admission of the New Shares on AIM is expected to become effective at 8.00 a.m. on 5 February 2021, following which there will be in total 47,292,939 ordinary shares in the capital of the Company in issue, each carrying equal voting rights.
This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, IXICO under the FCA's Disclosure and Transparency Rules.
The below makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:
Details of PDMR transaction
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Sylke Grootoonk
2
Reason for the notification
a)
Position/status
PDMR (VP Alliance Management)
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
IXICO plc
b)
LEI
2138005M1F59O6HWSA97
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Ordinary Shares in IXICO plc
Identification code
GB00BCLY7L40
b)
Nature of the transaction
Exercise of options
c)
Price(s) and volume(s)
Exercise Price(s)
Volume(s)
30.5p
112,942
34.0p
43,529
d)
Aggregated information
- Aggregated volume
156,471 shares
- Price
31.5p
e)
Date of the transaction
5 Feburary 2021
f)
Place of the transaction
N/A
For further information please contact:
IXICO plc
+44 (0)20 3763 7498
Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser and sole broker)
+44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Russell Kerr (Sales)
Walbrook PR Ltd
+44 (0)20 7933 8780
Paul McManus / Lianne Cawthorne /
Alice Woodings
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.
More information is available on www.IXICO.com and follow us on Twitter @IxicOplc
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDDSHDKCBDKBKDADB
Recent news on IXICO
See all newsREG - IXICO plc - Trading Update
AnnouncementREG - IXICO plc - Share option awards and PDMR Dealing
AnnouncementREG - IXICO plc - FDA Clearance of Alzheimer's Diagnostic Biomarker
AnnouncementREG - IXICO plc - Holding(s) in Company
AnnouncementREG - IXICO plc - Half-year Report
Announcement